Vitamin D At 10 mcg: 400 IU, And What It Adds To A Supplement You Already Take
Ten micrograms is 400 IU. Here is how far that is from the allowance, the ceiling and the doses in the large trials, and how to add it to a product you already have.
From micrograms to IU, and what the reference points are
The Gelagen panel prints vitamin D as cholecalciferol, 10 mcg per serving, and the serving is two gummies. Most vitamin D products sold to consumers are labelled in international units instead, and the conversion is a fixed one: 1 mcg of vitamin D is 40 IU. So 10 mcg is 400 IU, the same figure printed on a great many family-size bottles.
That conversion is the whole of the arithmetic, and it is worth having in your head because the next step is to compare it with three reference figures that different documents state in different units. The Daily Value on a US label is 20 mcg, which makes this row 50 per cent of it. The Recommended Dietary Allowance for adults up to 70 is 15 mcg, or 600 IU, so the row is two thirds of the allowance. The Tolerable Upper Intake Level is 100 mcg, or 4,000 IU, and the row is a tenth of that.
| mcg a day | IU a day | The printed 10 mcg as a share | |
|---|---|---|---|
| Printed on this panel (cholecalciferol) | 10 | 400 | – |
| Daily Value | 20 | 800 | 50% |
| Recommended Dietary Allowance, adults to 70 | 15 | 600 | About 67% |
| Tolerable Upper Intake Level, adults | 100 | 4,000 | 10% |
Where do the allowance and the ceiling come from? A summary of the Institute of Medicine’s 2011 report by Ross and colleagues sets out the allowance: 600 IU a day for ages 1 to 70 and 800 IU a day from 71, corresponding to a blood level of at least 20 ng/mL (50 nmol/L), which the committee judged meets the needs of at least 97.5 per cent of the population. The allowance was derived on the assumption of minimal sun exposure, and the committee found that the evidence for benefits outside bone health was inconsistent and insufficient to inform requirements. It also noted that higher values were not consistently associated with greater benefit and that for some outcomes the relationship was U-shaped, with risks at both low and high levels.
The ceiling has been reviewed more recently in Europe. EFSA’s 2023 opinion settled on 100 mcg a day for adults, using persistent hypercalciuria (excess calcium in the urine) as the critical endpoint. It identified a lowest-observed-adverse-effect level of 250 mcg a day from two randomised trials and applied an uncertainty factor of 2.5 to reach the 100 mcg figure. So the American and European ceilings agree for vitamin D, which is not true of every nutrient on this panel.
How far 400 IU is from the doses the big trials used
People often meet vitamin D through trial headlines, so it helps to know where a 400 IU gummy sits against the doses those trials tested. The largest is the VITAL trial. Manson and colleagues gave 2,000 IU a day of vitamin D3 or a placebo to 25,871 US men aged 50 and over and women aged 55 and over, and followed them for a median of 5.3 years. That dose is 50 mcg, five times what this panel prints. The trial found no significant difference in invasive cancer (hazard ratio 0.96) or major cardiovascular events (0.97), and no excess of hypercalcemia or other adverse events.
An ancillary analysis, reported by LeBoff and colleagues, looked at fractures in the same population and found no significant effect on total fractures (hazard ratio 0.98), nonvertebral fractures or hip fractures, with no modification by baseline blood level. The participants were generally healthy and had not been selected for deficiency, low bone mass or osteoporosis. That is the important qualifier on both results: they describe what happened when an extra dose was added to people who mostly did not need one, not what happens when a shortfall is corrected.
Nothing in those trials says a 400 IU gummy does or does not do anything for a given person. They are simply the most useful yardstick for how a 400 IU row looks beside a serious dose, and the answer is that it is one fifth of it.
A Canadian trial went the other way, up towards the ceiling and past it. In the Calgary study Burt and colleagues randomised 311 healthy adults aged 55 to 70 to 400, 4,000 or 10,000 IU a day for three years. Blood levels stayed put on 400 IU, roughly 76 nmol/L at the start and 77 at three years. On 4,000 IU they rose from 81 to 132 nmol/L, and on 10,000 IU from 78 to 144. The higher doses were associated with slightly lower bone density at the radius rather than higher, and the authors concluded that the findings did not support a benefit of high-dose supplementation for bone health.
The companion safety analysis by Billington and colleagues found mild hypercalcemia in none of the 400 IU group, 3 per cent of the 4,000 IU group and 9 per cent of the 10,000 IU group, all of it resolving on retesting. Hypercalciuria was common and rose with dose, at 17, 22 and 31 per cent. Serum calcium and creatinine did not differ overall, and clinical adverse events were balanced across the arms. The authors concluded the overall safety profile was similar across doses, with the calcium findings more frequent at higher ones.
Read together, the two Calgary papers put a 400 IU intake at the quiet end of the range: a level that held blood values steady in those adults and produced none of the calcium findings that appeared as doses climbed. That is a description of a small dose, not an endorsement of it and not a warning about it.
What ten micrograms does to a blood level
If you already know your blood level, the natural next question is how far one more 10 mcg moves it. There is one careful answer, and it comes with caveats. Heaney and colleagues gave 67 men in Omaha 0, 25, 125 or 250 mcg of cholecalciferol a day for about 20 weeks in winter and measured their blood levels of 25-hydroxyvitamin D. From a mean baseline of 70.3 nmol/L, the equilibrium level rose in direct proportion to the dose, by roughly 0.70 nmol/L for each additional microgram.
Multiply that slope by 10 and a 10 mcg addition would raise the average level by about 7 nmol/L, or a little under 3 ng/mL, since 1 ng/mL is about 2.5 nmol/L. The authors also estimated that about 12.5 mcg (500 IU) a day of oral input was needed to sustain the starting level over that winter.
Now the caveats, because every one of them matters. It was 67 men, at one latitude, in one season, with doses far higher than this one. The number is a group average and individuals varied around it. The rise takes weeks to show up, which is why the study ran for 20. And it says nothing about anyone whose baseline is very low or very high, since the response depends on where you start. The honest use of the figure is an order-of-magnitude one: an extra 10 mcg is a nudge of a few ng/mL on average, not a lever that moves a number by tens.
If you already take vitamin D, this is how to add up
Plenty of readers arrive with a bottle of vitamin D in the cupboard already, sometimes a stand-alone tablet and sometimes a multivitamin or a calcium product that carries its own. The question then is not whether 10 mcg is a lot. It is what the sum comes to, and the sum needs three steps.
- Put everything in the same unit. Convert IU to mcg by dividing by 40, or mcg to IU by multiplying. Write each product’s figure down.
- Add the gummy’s 10 mcg to the total from the other products. Count each product for the number of servings you actually take, not one.
- Compare the total with the ceiling of 100 mcg, or 4,000 IU. Food adds a little to a real day’s intake, and the ceiling is a limit and not a target.
| Second product, as labelled | Its vitamin D | Plus 10 mcg here | In IU | Against the 100 mcg ceiling |
|---|---|---|---|---|
| A multivitamin at 10 mcg (400 IU) | 10 mcg | 20 mcg | 800 | 20% |
| A tablet at 25 mcg (1,000 IU) | 25 mcg | 35 mcg | 1,400 | 35% |
| A tablet at 50 mcg (2,000 IU) | 50 mcg | 60 mcg | 2,400 | 60% |
| A tablet at 100 mcg (4,000 IU) | 100 mcg | 110 mcg | 4,400 | 110% |
| A capsule at 125 mcg (5,000 IU) | 125 mcg | 135 mcg | 5,400 | 135% |
The second products in that table are illustrations chosen so the percentages are easy to follow, not descriptions of any brand. The lesson is in the shape. With most ordinary companion products the gummy adds a sliver to a total that stays comfortably inside the ceiling, and it only changes the picture when the other product already sits at or near 100 mcg. At that point the 10 mcg is not the issue. The issue is that the first product was already at the limit.
A second habit is worth adopting. A serving here is two gummies, and a serving of some other product may be one tablet or a scoop. It is very easy to add the wrong number of servings, and the fix is to write the sum down once, with the servings in it, and keep it.
It is also worth remembering what the ceiling is calibrated for. The hypercalciuria that both the European review and the Calgary trial describe is a laboratory finding that shows up before symptoms do. EFSA describes it as possibly an earlier sign of excess vitamin D than raised blood calcium, which is one reason it makes sense to keep a running total in your head instead of waiting for a test to say so.
What a 25-hydroxyvitamin D result does and does not tell you
Many people who take vitamin D have, at some point, been given a blood result: 25-hydroxyvitamin D, often written 25(OH)D. It is the standard marker of vitamin D status, and it reflects the total from sun, food and supplements over the previous weeks, which is precisely why it cannot tell you where any of it came from. A result does not say how much of your level is due to the gummy, the tablet or a summer holiday.
It also comes with a warning that laboratory medicine has made for years. Binkley and colleagues compared results across laboratories and found that samples from clinically similar postmenopausal women averaged 46 ng/mL in one laboratory and 21 ng/mL in another, and that against an arbitrary threshold of 32 ng/mL, 17 per cent of one group and 90 per cent of the other counted as low. In a second experiment, aliquots of the same ten samples sent to six laboratories gave mean values from 17.1 to 35.6 ng/mL. Their conclusion was that whether a person is found to have low or normal status is a function of the laboratory used. More than a decade later, an international review still describes assay variation as contributing to the chaos around defining low vitamin D.
The cut-offs are not settled either. The same review suggests that values below 12 ng/mL (30 nmol/L) are associated with a higher risk of rickets and osteomalacia, and that values between 20 and 50 ng/mL (50 to 125 nmol/L) appear safe and sufficient for skeletal health in the general population. The Institute of Medicine summary above uses 20 ng/mL as the level that meets the needs of nearly everyone. A 2024 consensus statement from an international vitamin D conference says plainly that optimal levels remain debated, that different societies recommend different targets, and that the lack of assay standardisation makes it harder to interpret the studies available.
Put plainly, a blood level is a useful snapshot for a person and a clinician who can see the whole picture. It does not turn a supplement into a prescription, it does not compare cleanly from one laboratory to the next, and it says nothing about hair or skin. If you have a result, the practical use of this post is small: you now know that 10 mcg of extra intake would be expected to move it by a few ng/mL on average, over weeks, and that a difference of that size is much smaller than the spread between laboratories reported above.
What this comparison does not say
- It does not say the panel is designed to fix a deficiency. At 400 IU it is a modest contribution to a day, and the printed amount is below the allowance.
- It does not say vitamin D helps skin or hair. The panel makes no such claim in this row, and no trial of the finished product exists. Trial results quoted above concern bone, cancer and cardiovascular outcomes in older adults, and they found no benefit.
- It does not say more is better, or that less is. The Institute of Medicine noted that higher blood values were not consistently associated with greater benefit, and the Calgary trial found nothing to encourage large doses.
- It does not say anything about your own level. Only a measurement, interpreted by someone who knows your history, can do that.
What it does say is arithmetic, and arithmetic is a good place to end. Ten micrograms is 400 IU, which is two thirds of the allowance and a tenth of the ceiling. Add the other vitamin D in your routine, in one unit, with the right number of servings, and compare the total with 100 mcg. If it comes out well below, there is nothing more to work out. If it does not, that is a conversation for a pharmacist or clinician, ideally with the bottles in hand.
If you take other supplements or prescription medicines, or have a condition that affects calcium or your kidneys, check the total with a pharmacist or clinician before changing anything. Gelagen is a dietary supplement for healthy adults aged 18 and over, it is not intended for anyone who is pregnant or nursing, and it is not intended to diagnose, treat, cure or prevent any disease.
Related reading on this journal. See also why closing a shortfall and adding to a full day are different questions and what a Daily Value is, and is not. The full printed panel is on the supplement facts page.
Gelagen
Every Gelagen amount on this page is printed per two-gummy serving. Nothing here is halved to produce a per-gummy figure.
Order GelagenSources for this article
- Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-58. PMID 21118827.
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Castenmiller J, et al. Scientific opinion on the tolerable upper intake level for vitamin D, including the derivation of a conversion factor for calcidiol monohydrate. EFSA J. 2023;21(8):e08145. PMID 37560437.
- Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al; VITAL Research Group. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33-44. PMID 30415629.
- LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, et al. Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med. 2022;387(4):299-309. PMID 35939577.
- Burt LA, Billington EO, Rose MS, Raymond DA, Hanley DA, Boyd SK. Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical trial. JAMA. 2019;322(8):736-745. PMID 31454046.
- Billington EO, Burt LA, Rose MS, Davison EM, Gaudet S, Kan M, Boyd SK, Hanley DA. Safety of high-dose vitamin D supplementation: secondary analysis of a randomized controlled trial. J Clin Endocrinol Metab. 2020;105(4):dgz212. PMID 31746327.
- Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77(1):204-210. PMID 12499343.
- Binkley N, Krueger D, Cowgill CS, Plum L, Lake E, Hansen KE, DeLuca HF, Drezner MK. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab. 2004;89(7):3152-3157. PMID 15240586.
- Sempos CT, Heijboer AC, Bikle DD, Bollerslev J, Bouillon R, Brannon PM, et al. Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. Br J Clin Pharmacol. 2018;84(10):2194-2207. PMID 29851137.
- Giustina A, Bilezikian JP, Adler RA, Banfi G, Bikle DD, Binkley NC, et al. Consensus statement on vitamin D status assessment and supplementation: whys, whens, and hows. Endocr Rev. 2024;45(5):625-654. PMID 38676447.
Sourced from the product label and PubMed-indexed research. Gelagen amounts are read from the printed supplement facts panel. Every study above is listed with its PubMed number, and no claim here goes beyond what those records state.